Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial

Overview of attention for article published in Stem Cell Research & Therapy, May 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#13 of 2,833)
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 18,590 followers.

RT @Brandon_Beaber: A small randomized trial for intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS. No benefit…

RT @Brandon_Beaber: A small randomized trial for intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS. No benefit…

RT @Brandon_Beaber: A small randomized trial for intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS. No benefit…

RT @Brandon_Beaber: A small randomized trial for intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS. No benefit…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.